Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 31: 687-690, 1985;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eerdekens, M. W.
Right arrow Articles by De Broe, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eerdekens, M. W.
Right arrow Articles by De Broe, M. E.

Clinical Chemistry, Vol 31, 687-690, Copyright © 1985 by American Association for Clinical Chemistry

Placental alkaline phosphatase and cancer antigen 125 in sera of patients with benign and malignant diseases

MW Eerdekens, EJ Nouwen, DE Pollet, TW Briers and ME De Broe

Human placental alkaline phosphatase (hPLAP; EC 3.1.3.1), cancer antigen 125 (CA 125), and carcinoembryonic antigen (CEA) were determined in sera of patients with malignant and nonmalignant disorders. For CA 125 we used two different commercial assay systems, based on the same monoclonal antibody. hPLAP had the same sensitivity (20%) as CA 125 for detecting non-ovarian neoplasia, whereas that of CEA was 45%. For detecting ovarian cancer CA 125 (Cis kit) was slightly more sensitive (50%) than hPLAP (45%), much more than CEA (10%). hPLAP was increased in sera of 2% of patients with nonmalignant disorders, CA 125 in 23%, and CEA in 18%. hPLAP was increased in only one of 10 diabetic patients and two of 50 patients on chronic renal dialysis. CA 125 and CEA were respectively increased in 45% and 23% of all liver pathologies studied and in 12% and 17% of patients with renal insufficiency. The sensitivity of hPLAP for detecting ovarian cancer is slightly inferior to that of CA 125, but its specificity is much higher. We found the Abbott system for CA 125 to be more sensitive than the Cis system.


The following articles in journals at HighWire Press have cited this article:


Home page
 Cancer Res.Home page
P. Pospisil, K. Wang, A. F. Al Aowad, L. K. Iyer, S. J. Adelstein, and A. I. Kassis
Computational Modeling and Experimental Evaluation of a Novel Prodrug for Targeting the Extracellular Space of Prostate Tumors
Cancer Res., March 1, 2007; 67(5): 2197 - 2205.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
L. Soma, M. Allen, L. Tobin, C. Ganster, M. Bulley, J. Hunt, L. J. Kricka, M. Senior, and A. Kao
CA-125 Concentrations in Patients Awaiting Cardiac Transplantation
Clin. Chem., December 1, 2002; 48(12): 2289 - 2290.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Petäjä, S. Pitkänen, K. Vettenranta, A. Fasth, and M. Heikinheimo
Serum Tumor Marker CA 125 Is an Early and Sensitive Indicator of Veno-Occlusive Disease in Children Undergoing Bone Marrow Transplantation
Clin. Cancer Res., February 1, 2000; 6(2): 531 - 535.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American Association for Clinical Chemistry.